МЕСТО P-FOX-ИНГИБИТОРОВ СВОБОДНЫХ ЖИРНЫХ КИСЛОТ – В КОМБИНИРОВАННОЙ ТЕРАПИИ СЕРДЕЧНО-СОСУДИСТЫХ ОСЛОЖНЕНИЙ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2 ТИПА

1. Zimmet P., Ekoé J-M, Williams, R. Chichester: The Epidemiology of Diabetes Mellitus: An International Perspective. International Journal of Epidemiology 2002; 31: 878.

2. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.

3. Дедов И.И. Диабет как фактор риска сердечно – сосудистых заболеваний. Сердечная недостаточность 2003; 1: 12-15.

4. American Diabetes Association; National Heart, Lung and Blood Institute; Juvenile Diabetes Foundation International; National Institute of Diabetes and Digestive and Kidney Disease; American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation 1999; 100: 1132-1133.

5. Rosano G.M. et al. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Amer. J. Cardiology 2006; 98: 14-18

6. Stamler J., Vaccaro O., Neaton J.D. et al. for the Multiple Risk Factor Intervention Trial Research Group: Diabetes, other risk factors, and 12–yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444

7. Despres J.P, Lamarche B., Mauriege P., et al. Risk factors for ischaemic heart disease: is it time to measure insulin? Eur Heart J 1996;17:1453-1454.

8. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 2003; 11: 1278–1289.

9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703–713.

10. Дедов И.И., Шестакова М.В. Сахарный диабет. М.: Универсум Паблишинг, 2003.

11. Ярек – Мартынова И.Р., Шестакова М.В. Сахарный диабет и эндотелиальная дисфункция. Сах. диабет. 2004; 2: 48–52.

12. Trost S., Pratley R., Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Current Diabetes Reports 2006; 6: 47–54.

13. Bonetti P.O, Lerman L.O, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology 2003; 23: 168–175.

14. Randriamboavonjy V., Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care 2009; 32: 528–530.

15. Dickinson S., Brand-Miller J. Glycemic index, postprandial glycemia and cardiovascular disease.Curr Opin Lipidol. 2005; 16(1):69-75.

16. Chien K.L, Lee B.C, Lin H.J, et al. Association of fasting and postprandial hyperglycemia on the risk of cardiovascular and all-cause death among non-diabetic Chinese. Diabetes Res Clin Pract. 2009; 83(2): 47-50.

17. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetic Med. 16. 1999.

18. Barret-Connor E. Awards and Named Lecturers at the American Heart Association 69th Scientific Sessions. Cardiovascular News Circulation 1997; 95(5):1091-1094

19. Qiao Q., Tuomilehto J., Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003; 46 Suppl 1: 17-21

20. Gao W, Qiao Q, Tuomilehto J. Post-challenge hyperglycaemia rather than fasting hyperglycaemia is an independent risk factor of cardiovascular disease events. Clin Lab. 2004;50(9-10):609-15.

21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837

22. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. New Engl. J. Med. 2008; 358: 2545–2559

23. Александров А.А. Сахарный диабет: болезнь ‘взрывающихся’ бляшек. Consilium Medicum 2001; 1:4 -10.

24. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005; 294: 334–341.

25. Gianluca Perseghin, Georgia Ntali, Francesco De Cobelli, Guido Lattuada, еt al. Abnormal Left Ventricular Energy Metabolism in Obese Men With Preserved Systolic and Diastolic Functions Is Associated With Insulin Resistance. Diabetes Care 2007 30:1520-1526.

26. Witteles Ronald M, Fowler Michael B. Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options. J Am Coll Cardiol. 2008;51(2):93-102

27. Stender M., Eaton S., Clark D., Hopkinson P. Cardiovascular risk factors and outcomes in type 2 diabetes patients in primary care. The future of diabetes care. Selected Abstracts of the 36th Annual Meeting from the Europian Association for the Study of Diabetes, 2000; poster 1073:9.

28. Chisolm G.M, Irwin K.C, Penn M.S. Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes. 1992;41 Suppl 2:61-66.

29. Ehara S., Ueda M., Naruko T., et al Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases Journal of Diabetes and its Complications 2002;16 (1): 60-64.

30. Matsumoto Tetsuya, Takashima Hiroyuki, Ohira Naoto., et al. Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin Am. Coll. Cardiol. 2004; 44:451-457.

31. Morrison A., Hokanson John E. The independent relationship between triglycerides and coronary heart disease Vasc Health Risk Manag. 2009; 5: 89–95.

32. Rutger W. van der Meer, Luuk J. Rijzewijk, Michaela Diamant, et al. The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. European Heart Journal 2008; 29: 1516–1522.

33. Timothy D. Wiggin, Kelli A. Sullivan, Rodica Pop-Busui et al. Elevated Triglycerides Сorrelate With Progression of Diabetic Neuropathy. Diabetes July 2009; 58 (7):1634-1640.

34. Voulgari C., Psallas M., Kokkinos A., et al. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications 2010; 11: [Epub ahead of prin].

35. Suskin N,, McKelvie R.S., Burns R.J., et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure Eur Heart J 2000;21:1368-1375.

36. Miles J.M., Nelson R.H. Contribution of triglyceride-rich lipoproteins to plasma free fatty acids. Horm Metab Res. 2007; 39 (10):726 – 729.

37. Bell D. S.H. Diabetic Cardiomyopathy Diabetes Care 2003, 26:2949- 2951.

38. Candido R., Forbes J.M., Thomas M.C., et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92:785–792.

39. Young M.E., McNulty P., Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes. Part II. Potential mechanisms. Circulation 2002; 105:1861–1870.

40. Leichman J.G., Aguilar D., King T.M. et al. Association of plasma free fatty acids and left ventricular diastolic function in patients with clinically severe obesity. Am J Clin Nutr. 2006; 84 (2):336-341.

41. С остальными источниками (41-187) можно ознакомиться в редакции.